RELAY研究:厄洛替尼联合雷莫西尤单抗或安慰剂治疗未经治疗的EGFR突变转移性非小细胞肺癌的最终总生存分析
RELAY是一项全球双盲安慰剂对照3期研究,纳入未经治疗的EGFR突变转移性非小细胞肺癌患者449例,随机接受厄洛替尼联合雷莫西尤单抗或安慰剂。最终总生存分析显示两组中位总生存期分别为51.1个月和46.0个月,风险比为0.98(95%CI 0.78-1.24,P=0.864),差异无统计学显著。
要点
- RELAY最终分析显示,雷莫西尤单抗联合厄洛替尼组与安慰剂联合厄洛替尼组的总生存期无显著改善。
- 两组中位总生存期分别为51.1个月和46.0个月,风险比为0.98(95%CI 0.78-1.24)。
- L858R或TP53共突变亚组的总生存期呈现方向性改善,但置信区间均跨1。
核心结论
- 在RELAY研究中,雷莫西尤单抗联合厄洛替尼组与安慰剂联合厄洛替尼组的总生存期无显著改善,两组均观察到相似的长总生存期。
研究设计与样本
- RELAY是一项全球双盲、安慰剂对照的3期研究(NCT02411448)。
- 2016年1月至2018年2月期间,449例携带EGFR外显子19缺失或L858R突变且无中枢神经系统转移的未经治疗患者按1:1随机分组。
- 雷莫西尤单抗联合厄洛替尼组224例接受厄洛替尼150 mg/天联合雷莫西尤单抗10 mg/kg每两周一次;安慰剂联合厄洛替尼组225例接受厄洛替尼联合安慰剂。
主要发现
- 数据截止时报告297例死亡(总事件率66%),中位随访时间45.1个月(四分位距26.7-71.2)。
- 总生存风险比为0.98(95%CI 0.78-1.24,P=0.864),中位总生存期雷莫西尤单抗联合厄洛替尼组为51.1个月,安慰剂联合厄洛替尼组为46.0个月。
- L858R亚组风险比为0.87(95%CI 0.62-1.22),外显子19缺失亚组风险比为1.13(95%CI 0.83-1.55)。
- TP53共突变亚组风险比为0.83(95%CI 0.58-1.19),TP53野生型亚组风险比为1.22(95%CI 0.87-1.72)。
- 两治疗组治疗中出现T790M的比例相似,超过80%的患者接受了研究后停药治疗,其中超过50%接受奥希替尼且两组人数相当。
关键数值与推荐
- 总生存风险比为0.98(95%CI 0.78-1.24,P=0.864),未达统计学显著。
- 中位总生存期雷莫西尤单抗联合厄洛替尼组51.1个月 vs 安慰剂联合厄洛替尼组46.0个月。
- L858R亚组风险比0.87(95%CI 0.62-1.22),外显子19缺失亚组风险比1.13(95%CI 0.83-1.55)。
- TP53共突变亚组风险比0.83(95%CI 0.58-1.19),TP53野生型亚组风险比1.22(95%CI 0.87-1.72)。
临床怎么用
- 雷莫西尤单抗联合厄洛替尼的安全性与既往报告一致,未观察到随时间增加的毒性或新的安全信号。
局限性
- L858R或TP53共突变亚组的总生存期改善仅为方向性,置信区间均跨1。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: RELAY, a global double-blind, placebo-controlled phase 3 study (NCT02411448) found statistically significant improvement in progression-free survival (primary end point) for ramucirumab (RAM) plus erlotinib (ERL) (RAM + ERL) in patients with untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59, 95% confidence interval [CI]: 0.46-0.76, p < 0.0001; median progression-free survival: 19.4 versus 12.4 mo). Here, we report the final overall survival (OS; secondary end point) outcomes for the intention-to-treat population. METHODS: Between January 2016 and February 2018, 449 eligible patients with an EGFR exon 19del or L858R mutation and no central nervous system metastases were randomized (1:1) to ERL (150 mg/day) with RAM (10 mg/kg every two weeks, N = 224) or placebo (N = 225). RESULTS: At data cutoff, 297 deaths were reported (overall event rate = 66%), with a median follow-up of 45.1 months (interquartile range: 26.7-71.2), an OS HR of 0.98 (95% CI: 0.78-1.24, p = 0.864), and median OS of 51.1 months (RAM + ERL) and 46.0 months (placebo + ERL). Outcomes in subsets of patients with poor prognosis (L858R or TP53 co-mutation) suggest a directional improvement in OS (L858R: HR = 0.87, 95% CI: 0.62-1.22; exon 19del: HR = 1.13, 95% CI: 0.83-1.55; TP53 co-mutation: HR = 0.83, 95% CI: 0.58-1.19; TP53-wild-type: HR = 1.22, 95% CI: 0.87-1.72). Treatment-emergent T790M rates were similar between arms. Over 80% of patients received post-study discontinuation therapy (>50% received osimertinib in comparable numbers between arms). The safety profile for RAM + ERL was consistent with previous reports with no increased toxicity over time or new safety signals observed. CONCLUSION: In RELAY, OS was not significantly improved with similar long OS durations in both treatment arms. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT02411448.
引用
- Nakagawa K, Garon EB, Seto T, et al. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2024. PMID: 39622410. doi:10.1016/j.jtho.2024.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。